At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 5,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 3
- ✓Age greater than 18 years
- ✓Histologically verified pancreatic ductal adenocarcinoma or ampullary adenocarcinoma in resected specimen
- ✓Histopathological confirmation of carcinoma in patients not undergoing surgery with clinical and radiological characteristics consistent with PC diagnosis
Key exclusion· 0
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?
In Brief
An observational study for Pancreatic Cancer. Currently recruiting, targeting 5,000 participants across 1 site.
Detailed Summary
No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesDenmark
Collaborators--
Timeline
N/ARecruiting
20082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033203420352036
Enrollment StartJul 2008
First PostedOct 2017
TodayJul 2026
Primary CompletionJul 2035
First PostedOct 17, 2017
Enrollment StartJul 3, 2008
Primary CompletionJul 2, 2035
TodayJul 2, 2026
Enrollment to primary: 27.0 yearsPosted 8.7 years agoPrimary completion in 9 years